Abstract
Introduction
Pregnancy is a prothrombotic state, likely arising from a physiological response to reduce the risk of bleeding during the antenatal, and particularly the postnatal, period. As a result, pregnant women are at increased risk of venous thrombosis compared to the general population. Epidemiological data suggests that hypercoagulability begins early in pregnancy, with an increase in thrombotic risk beginning in the first trimester [1] [2] [3] . However, it is unknown exactly how early in pregnancy that the hypercoagulable state begins to develop.
Thrombin generation, a global coagulation assay, has been demonstrated to more accurately reflect the thrombotic phenotype than measuring individual parameters of the coagulation cascade [4] [5] [6] [7] [8] . Thrombin is pivotal to the coagulation cascade; it is the enzyme responsible for converting fibrinogen to fibrin, the step resulting in clot formation. Thrombin also has numerous positive and negative feedback roles across the coagulation cascade, thus making it central to this process. It is therefore reasonable to expect that an assessment of an individual's ability to generate thrombin will provide an accurate evaluation of an individual's potential to clot.
Studies assessing thrombin generation during pregnancy have been undertaken but have had various limitations in their findings [7, [9] [10] [11] [12] [13] [14] . Rarely has thrombin generation been assessed earlier than 10 weeks of gestation, the late stage of the first trimester, and most studies have not obtained pre-pregnancy samples from the same women, preventing an account to be taken of the known significant inter-individual variability in thrombin generation [15] [16] .
Frequently the demonstration that pregnancy is associated with an increase in thrombin generation has been through comparisons of thrombin generation results obtained from either normal pooled plasma or from using postpartum samples from the previously pregnant women [9, [11] [12] [13] [14] . Other potential confounders such as the use of low molecular weight heparin (LMWH) have also affected data [12] [13] .
In only one study have the same women been recruited pre-pregnancy and then followed up with samples taken during pregnancy [10] . In this study, thrombin generation was significantly increased in 20 healthy pregnant women at 11-15 weeks of gestation when compared to measurements taken in the same women prior to pregnancy. However, to date, no similar comparisons have been made at an earlier gestation. Furthermore, although this study compared mean thrombin generation values between pre-pregnancy and pregnancy, it did not report the mean change in thrombin generation per individual over this time period, and therefore the significant inter-individual variability known to occur in thrombin generation was not accounted for.
Our study is a prospective analysis of thrombin generation in women undergoing natural cycle in vitro fertilization, as such women provide the most practical method of obtaining, to an extent, accurately timed peri-conceptual and early pregnancy samples and are the best physiological representation of a 'normal' pregnancy, outside a free living population. These women subsequently gave birth at term following a normal pregnancy.
Our aim was to explore the time of onset of increased thrombin generation in pregnancy, as an indication of the development of the prothrombotic state, and in turn, guide clinicians as to how early preventative measures should be taken in pregnant women at high risk of thrombosis. 
Materials and Methods

CAT Reagents
Blood Samples
Blood samples were collected in sodium citrate, centrifuged at 3000 rpm for 15 minutes at 4ºC within 2 hours of plasma collection. Plasma was then spun in a microfuge at 13,000 rpm for 4 minutes to obtain platelet poor plasma (PPP) and stored at -80ºC. Two pre-pregnancy 
Calibrated Automated Thrombography (CAT)
Thrombin generation (TG) was measured according to the method previously described by Hemker in a Fluoroskan Ascent TM fluorometer (Thermo Labsystems OY, Helsinki, Finland) [15] . Fluorescence intensity was detected at 390 nm (excitation) and 460 nm (emission).
Briefly, 20 ml of TCal or 20 ml of PPPLow or PPP reagent, in the presence or absence of 0.4nM TM or 1.37nM TM respectively, were dispensed into a round bottom 96 well microtitre plate, where the concentration of TM used was determined as previously described [17] . Eighty microlitres of either TGT-RP or PPP was then added to each mixture and pre- All samples from each woman were assessed concurrently, alongside a standardised plasma (TGT-RP), to minimise the effect of inter-assay variability.
The TG parameters measured were; endogenous thrombin potential (ETP) (nM.min, the area under the curve), Peak thrombin concentration (nM), lag time (min, time to first thrombin production), time to reach peak height (ttPeak) (min), Velocity Index (VI) (nmol/min, slope between lag time and ttPeak) and start tail (min, time at which thrombin generation ceases).
Statistical Analysis
Thrombin generation test results were collected from individual experiments for statistical analysis. The mean, standard deviation and confidence interval were calculated for all TG parameters under 4 different assay conditions. One-Way ANOVA comparison (Dunnett's test and Tukey's test) was performed using GraphPad Prism Version 6.07 where statistical significance was given a P-value of < 0.05.
Results
women were recruited, resulting in 36 successful first attempt pregnancies, of which 22
women gave birth at term with no complications occurring during the antenatal period.
Demographic data for these 22 women is shown in Table 1 , including the reason for IVF.
Effect of Pregnancy on Thrombin Generation
Thrombin generation was measured in 19 separate experiments, where all samples were tested in parallel with TGT-RP, under the 4 different assay conditions. To limit the effect of inter-assay variability, all samples from each individual woman were assessed concurrently.
Intra-assay coefficient of variation (CV) for TGT-RP was less than 5% for all TG parameters and inter-assay CV ranged between 4% -19% (data not shown).
On analysis of the mean data, there was a significant increase from baseline (average of 
Discussion
Our data demonstrates that thrombin generation increases in women at a very early stage of pregnancy, at approximately five weeks of gestation, and that this increase persists to eight weeks of gestation. This change is detectable using four of the more commonly used thrombin generation assay conditions, 1pM and 5pM TF +/-TM, the lower concentration of tissue factor highlighting the intrinsic pathway, the higher concentration, the extrinsic pathway. The addition of thrombomodulin enables evaluation of the positive feedback effect of thrombin on the Protein C/Protein S pathway.
Ours is the first study to demonstrate the very early stage of pregnancy at which thrombin generation patterns begin to change. Previous studies have captured data almost exclusively during the late stage of the first or the early stage of the second trimester [7, [9] [10] [11] [12] [13] [14] .
Furthermore, ours is the first to capture such data in a longitudinal setting and obtain pregnancy outcome data.
The majority of previous studies have not been longitudinal and/or do not capture prepregnancy samples from women who are subsequently followed up during pregnancy [7, 9, [11] [12] [13] [14] . Frequently the demonstration that pregnancy is associated with an increase in thrombin generation has been derived from control pooled plasma either from men, nonpregnant women or a postpartum sample from the previously pregnant women [9, 11-14].
The use of control pooled plasma or postpartum samples to demonstrate changes in thrombin generation during pregnancy is not a valid or reliable comparison due to significant interindividual variability in thrombin generation. Finally, in many of these studies, thrombin generation assay conditions were not standardised, and/or did not include a standardised control plasma, which will also affect the validity of the results given the known intra and inter assay variation that can occur when assessing thrombin generation [18, 19] .
This is the first study to accurately compare pre-pregnancy and pregnancy results by assessing percentage change from baseline, thereby taking account of the important issue of inter-individual variability in thrombin generation. The data shown in Table 2 The parameters of thrombin generation which demonstrated a significant change were peak, ETP and VI. Lag time, ttPeak and Start Tail were not significantly affected. This may suggest that the total amount of thrombin generated rather than the time at which thrombin is generated is more significant in the underlying hypercoagulable state of pregnancy.
The prothrombotic state of pregnancy has previously been demonstrated using other laboratory markers [20] [21] [22] . Protein S and VIII are known to decrease and increase respectively in response to pregnancy although it is unknown exactly at what stage of pregnancy these changes occur. If these factors do alter at a similar gestation as thrombin generation, this would provide evidence that these changes are contributing to the prothrombotic state. By using lower levels of tissue factor i.e. 1pM as opposed to 5pM, and thrombomodulin, in some of the assay conditions, we hope to have captured the effect these two proteins have on thrombin generation by highlighting the effect of the intrinsic pathway and the activated protein C pathway, respectively. High levels of tissue factor and the absence of thrombomodulin however, still enabled a change in thrombin generation to be detected suggesting that changes in protein S and VIII are not the only variations in coagulation parameters that result in the prothrombotic state of pregnancy. Further work is required to assess how early other parameters involved in the coagulation cascade change in pregnancy.
Some previous longitudinal studies have been performed where thrombin generation has been measured on more than one occasion in the same women during the pregnancy. These studies have not concurred as to whether thrombin generation increases significantly as pregnancy progresses which may in part be due to a lack of standardization in experimental design [7, [9] [10] [11] [12] [13] [14] . Our study also suggests that thrombin generation may continue to increase as pregnancy
progresses. This appears to be best reflected when thrombin generation is assessed under 5pM assay conditions; ETP, peak and VI increased significantly between Day 18 and Day 45 using 5pM +TM but such significant changes were only demonstrable for ETP under lower tissue factor conditions ( Table 4) . This is perhaps surprising given that both concentrations of tissue factor could detect thrombin generation changes between the pre-pregnant and pregnant state. On review of our results we hypothesise that changes detected in thrombin generation between different time points during pregnancy and under some assay conditions may be affected by patient numbers and differences in confidence intervals. One further limitation of our study was samples were not taken beyond the early 1 st trimester to characterise to thrombin generation patterns as pregnancy progress. Further work is still required in this area.
Our results suggest that hypercoagulability associated with pregnancy begins as early as four weeks of gestation, which is around the time of a first positive pregnancy test. We do not suggest from our results that thrombin generation can predict which women are at increased risk of venous thrombosis; simply that, those women deemed to be at high thrombotic risk, based on currently available clinical guidelines, will develop that higher risk very early in pregnancy. This is an important finding as it has previously been acceptable practice for those women deemed at high risk of venous thrombosis in association with pregnancy to start prophylaxis with low molecular weight heparin (LMWH) after the confirmation of a pregnancy on ultrasound, around 8-12 weeks of gestation. This study suggests that waiting to confirm a pregnancy on scan may be later than is safe to commence LMWH. Therefore we suggest that, as a result of this work, women deemed to be at high risk of thrombosis during pregnancy should commence thromboprophylaxis as soon as pregnancy is verified by a positive urinary pregnancy test. We believe that the chance of either a false positive pregnancy result or side effects from LMWH are outweighed by the benefits gained from receiving LMWH as early as possible and preventing a first trimester venous thrombosis. Venous thrombosis remains the third most common cause of maternal death with 25% of deaths occurring in the first trimester [23] . Furthermore there is significant morbidity associated with venous thrombosis in pregnancy, in particular post thrombotic syndrome, which is often more severe in pregnant women than their non pregnant counterparts due to the more proximal location of thromboses which occur in the pregnant state. The early introduction of LMWH may have the potential to reduce this rate of significant morbidity and even mortality. 
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